Please use this identifier to cite or link to this item:
Title: Usefulness of Isosorbide Dinitrate and Hydralazine as Add-on Therapy in Patients Discharged for Advanced Decompensated Heart Failure
Authors: MULLENS, Wilfried 
Abrahams, Zuheir
Starling, Randall C.
Young, James B.
Taylor, David O.
Tang, W. H. Wilson
Francis, Gary S.
Sokos, George
Issue Date: 2009
Source: AMERICAN JOURNAL OF CARDIOLOGY, 103 (8), p. 1113-1119
Abstract: Data supporting the use of oral isosorbide dinitrate and/or hydralazine (I/H) as add-on therapy to standard neurohormonal antagonists in advanced decompensated heart failure (ADHF) are limited, especially in the non-African-American population. Our objective was to determine if addition of I/H to standard neurohormonal blockade in patients discharged from the hospital with ADHF is associated with improved hemodynamic profiles and improved clinical outcomes. We reviewed consecutive patients with ADHF admitted from 2003 to 2006 with a cardiac index <= 2.2 L/min/m(2) admitted for intensive medical therapy. Patients discharged with angiotensin-converting enzyme inhibitors and/or angiotensin receptor blockers (control group) were compared with those receiving angiotensin-converting enzyme inhibitors/angiotensin receptor blockers plus I/H (I/H group). The control (n = 97) and I/H (n = 142) groups had similar demographic characteristics, baseline blood pressure, and renal function. Patients in the I/H group had a significantly higher estimated systemic vascular resistance (1,660 vs 1,452 dynes/cm(5), p <0.001) and a lower cardiac index (1.7 vs 1.9 L/min/m(2), p <0.001) on admission. The I/H group achieved a similar decrease in intracardiac filling pressures and discharge blood pressures as controls, but had greater improvement in cardiac index and systemic vascular resistance. Use of I/H was associated with a lower rate of all-cause mortality (34% vs 41%, odds ratio 0.65, 95% confidence interval 0.43 to 0.99, p = 0.04) and all-cause mortality/heart failure rehospitalization (70% vs 85%, odds ratio 0.72, 95% confidence interval 0.54 to 0.97, p = 0.03), irrespective of race. In conclusion, the addition of I/H to neurohormonal blockade is associated with a more favorable hemodynamic profile and long-term clinical outcomes in patients discharged with low-output ADHF regardless of race. (C) 2009 Elsevier Inc. (Am J Cardiol 2009;103: 1113-1119)
Notes: [Abrahams, Zuheir; Starling, Randall C.; Young, James B.; Taylor, David O.; Tang, W. H. Wilson] Cleveland Clin, Kaufman Ctr Heart Failure, Dept Cardiovasc Med, Cleveland, OH 44106 USA. [Mullens, Wilfried] Ziekenhuis Oost Limburg, Dept Cardiol, Genk, Belgium. [Francis, Gary S.] Univ Minnesota, Div Cardiovasc Dis, Minneapolis, MN USA. [Sokos, George] Allegheny Gen Hosp, Gerald McGinnis Cardiovasc Inst, Pittsburgh, PA 15212 USA.
Keywords: Cardiac & Cardiovascular Systems
Document URI:
ISSN: 0002-9149
e-ISSN: 1879-1913
DOI: 10.1016/j.amjcard.2008.12.028
ISI #: 000265433300013
Category: A1
Type: Journal Contribution
Appears in Collections:Research publications

Show full item record


checked on Sep 7, 2020


checked on May 13, 2022

Page view(s)

checked on Feb 24, 2022

Google ScholarTM



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.